Press Releases

Press Releases

Date Title  
Jun 21, 2018

C3 Curriculum Designed for Physicians Specializing in Interventional Cardiology, Vascular Surgery and Interventional Radiology REDWOOD CITY, Calif. , June 21, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD),

Jun 14, 2018

SCAN Clinical Trial Results Intended to Support CPT Code Application for Incremental Diagnostic Reimbursement REDWOOD CITY, Calif. , June 14, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the

Jun 13, 2018

REDWOOD CITY, Calif. , June 13, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that Mark Weinswig will join the Company, and serve in the role of Chief Financial

May 30, 2018

REDWOOD CITY, Calif. , May 30, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced a schedule of sessions and posters highlighting the company’s Lumivascular technology at the New Cardiovascular

May 29, 2018

REDWOOD CITY, Calif. , May 29, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that it will be presenting at the 8 th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Bel Air,

May 23, 2018

The Pantheris Lumivascular Atherectomy System is the first-ever image-guided atherectomy device for treatment of peripheral artery disease REDWOOD CITY, Calif. , May 23, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease

May 14, 2018

REDWOOD CITY, Calif. , May 14, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the first quarter ended March 31 , 2018.   First Quarter and Recent Highlights Revenue of $1.8 million

May 04, 2018

REDWOOD CITY, Calif. , May 04, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the first quarter 2018 after the close of trading on Monday, May 14,

Apr 30, 2018

Charing Cross Symposium (CX) is the longest running vascular and endovascular symposium in Europe and one of the largest in the world REDWOOD CITY, Calif. , April 30, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease

Mar 29, 2018

Three patients successfully treated using next generation image-guided atherectomy device with enhanced tissue removal capacity for treatment of peripheral artery disease REDWOOD CITY, Calif. , March 29, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative